Physician profile
Wilfredo Cuevas
NPI 1720296718
$529,617.54
in general payments reported to CMS, 2019-2025
9 companies · $70K in 2025
The $70K reported for 2025 was more than what 99% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69K · 2020: $35K · 2021: $71K · 2022: $105K · 2023: $90K · 2024: $91K · 2025: $70K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $230K · Food and Beverage: $7,494 · Travel and Lodging: $7,072 · Consulting Fee: $5,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $230,265.00 |
| Food and Beverage | $7,494.43 |
| Travel and Lodging | $7,072.15 |
| Consulting Fee | $5,685.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $410,067.52 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Janssen Pharmaceuticals, INC | $85,389.69 | 2019-2023 | Symtuza |
| Janssen Scientific Affairs, LLC | $9,690.00 | 2020-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $8,810.40 | 2019-2023 | Isentress |
| Gilead Sciences, INC. | $7,881.09 | 2022-2025 | Biktarvy, Sunlenca |
| Janssen Products, Lp | $6,978.93 | 2019-2022 | |
| Theratechnologies INC. | $458.46 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $224.01 | 2021-2023 | Uptravi, Opsumit |
| Abbvie INC. | $117.44 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wilfredo Cuevas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.